Industries > Pharma > Parkinson’s Diseases: World Drug Industry and Market 2016-2026
Parkinson’s Diseases: World Drug Industry and Market 2016-2026
Parkinson’s Diseases: World Drug Industry and Market 2016-2026 – our new study reveals trends, R&D progress, and predicted revenues
Our new report discusses issues and events affecting the Parkinson’s disease therapeutics market. Our new report provides qualitative analyses to answer these key questions:
• How is the Parkinson’s disease therapeutics market evolving?
• What is driving and restraining the Parkinson’s disease therapeutics market?
• How will political and regulatory factors influence the regional markets and submarkets?
• Who are the leading Parkinson’s disease therapeutics companies, and what are their prospects over the forecast period?
• What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?
Forecasts from 2016-2026 and other analyses show you commercial prospects
Our new report provides quantitative analyses to answer these key questions:
• What are the market shares of the Parkinson’s therapeutics disease market in 2015?
• How will each of the drugs in the Parkinson’s therapeutics market grow over the forecast period and how much revenue will these drugs account for in 2026?
• What Parkinson’s disease drugs are in the development pipeline?
• How will each of Parkinson’s disease diagnostics market grow over the forecast period and how much revenue will these submarkets account for in 2026?
• How will the market shares of the national markets change by 2026 and which geographical region will lead the market in 2026?
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. We provide original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and STEP), company profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales.
Many opportunities exist for the treatment of Parkinson’s. Our new study shows you the most promising and lucrative parts of that CNS market, helping you stay ahead.
Discover sales predictions for the world market and submarkets
Discover in our report overall world revenue to 2026 for Parkinson’s disease medicines. Also explore individual revenue predictions to 2026 for five therapeutic submarkets at world level:
• Dopaminergic Agents
• Dopamine Receptor Agonists
• MAO-inhibitors
• COMT-inhibitors
• Other Therapeutic Options
Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.
See revenue forecasts for Parkinson’s disease drugs
How will individual medicines perform from 2016 to 2026 at world level? Our study forecasts revenues of three brands sold by four companies:
• Neupro (UCB)
• Azilect (Teva)
• Azilect (Lundbeck)
• Comtan/Stalevo (Novartis)
What are the prospects in the leading regions and countries?
Developments worldwide expand the market for diagnosing, treating and monitoring neurodegenerative disorders. Developed and developing national markets hold high potential from 2015.
Our work also shows individual revenue forecasts to 2026 for 11 national markets:
• United States (US)
• Japan
• EU leaders – Germany, France, the UK, Italy and Spain (EU5)
• BRIC nations – Brazil, Russia, India and China
Leading companies and potential for market growth
In 2015 the overall world PD drug market generated $3217m. Visiongain predicts its revenues in 2020 to reach $3472m. Our work shows you what organisation hold greatest potential. See profiles of leading companies in this sector:
• Novartis
• Teva
• UCB
• Roche
• Lundbeck
What affects producers of those medicines?
Our report discusses issues and events affecting that industry and market from 2015, including these:
• Research and development (R&D) – drugs, diagnostic tests, and related technologies
• Disease prevalence – expanding patient populations
• Disease-modifying drugs and obstacles to cures
• Regulatory guidelines – changes and opportunities.
• Drugs and related technologies to transform the market
• Biomarkers
• Deep brain stimulation (functional neuromodulation)
• Intellectual property (IP), licensing agreements and partnerships.
Our 172-page report provides 120 charts. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews trends and opportunities, and revenue predictions.
Benefit your work now through our updated study, gaining original industry and market analysis:
• Revenues for Parkinson’s disease treatments to 2026 – assess that overall world drugs market’s potential and get forecasted revenues for the five leading sub-classes: dopaminergic agents, dopamine receptor agonists, COMT- and MAO-inhibitors and other therapeutic options.
• Products’ sales to 2026 – discover predicted revenues Neupro, Comtan/Stalevo, and Azilect and see how those medicines can compete and succeed
• National market forecasting to 2026 for 11 countries in the Americas, Europe and Asia – explore the best regions for treatment demand, sales and growth
• R&D activities – see progress, trends and prospects in research and development, finding technological, clinical and commercial possibilities
• Companies, news and opinions – examine participants, including Roche, Novartis, UCB and Lundbeck and get two exclusive interviews, helping your reputation for insight and staying ahead. Visiongain interviewed:
– Dr. Russell Kern (Executive VP, Chief Scientific Officer): International Stem Cell Corporation, California, US
– Professor Jian Feng PhD, Department of Physiology and Biophysics, University at Buffalo, the State University of New York.
• Analysis of what stimulates and restrains that industry and market – assess challenges and strengths there, helping you compete and gain advantages.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Overview of Findings: World Market Overview 2015 to 2026
1.2 Why You Should Read This Report
1.3 How This Report Delivers: Chapter Outlines
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Parkinson’s Disease and its Treatments
2.1 What Causes Parkinson’s?
2.2 Motor Symptoms of Parkinson’s Disease
2.2.1 Tremor: The First Sign of PD
2.2.2 Uncontrolled Muscle Contractions Cause Rigidity
2.2.3 Bradykinesia: The Most Characteristic Feature of Parkinson’s
2.2.4 Postural Instability Manifests as PD Progresses
2.3 Neuropsychiatric Symptoms are Common in PD Patients
2.3.1 Behavioural Deficits are Often the Most Widespread
2.3.2 Cognitive Impairment can Impede Daily Tasks
2.3.3 Autonomic Dysfunction: Another Common Occurrence
2.4 Other Symptoms Associated with Parkinson’s
2.5 Parkinson’s Disease: Diagnosis and Treatment
2.5.1 Diagnosis is Difficult
2.5.2 Treatment Options – Therapeutic Classes
3. Parkinson’s Disease: World Drugs Market, 2016-2026
3.1 Sales of the Overall World PD Drugs Market, 2015-2026
3.2 Parkinson’s Disease: Market Segmentation, 2015
3.3 Overall PD Drug Market: Commercial Drivers and Restraints
3.4 Dopaminergic Agents: Foundation of PD Treatment
3.4.1 Levodopa Therapy
3.4.2 Patent Expiries Affect the Market
3.4.3 New Levodopa Therapies on the Horizon
3.4.4 Dopaminergic Agents: Market Projections to 2026
3.5 Dopamine Receptor Agonists: The Leading Class in 2016
3.5.1 Dopamine Agonists: A Front Line Drug
3.5.2 Advantages over L-Dopa Therapy
3.5.3 Leading Drugs in the Segment
3.5.4 A Healthy R&D Pipeline
3.5.5 Dopamine Receptor Agonists: Market Projections, 2016-2026
3.6 Catechol-O-Methyl Transferase (COMT) Inhibitors: A Popular Choice of Treatment
3.6.1 Entacapone: The Leading Drug in this Segment
3.6.2 Commercial Scope for COMT Inhibitors
3.6.3 COMT Inhibitors: Market Projections, 2016-2026
3.7 Are Monoamine Oxidase–B (MAO-B) Inhibitors Better Than COMT?
3.7.1 MAO-B Inhibitor Therapeutics in the Market
3.7.2 New MAO-B Products in Development
3.7.3 MAO-B Inhibitors: Market Projections, 2016-2026
3.7.4 Other Therapeutic Options: A Growing Opportunity
3.7.5 Generic Erosion in the PD Market
3.7.6 A Broad and Diverse Pharmaceutical Segment
3.7.7 Other Non-medication PD Therapies
3.7.8 The Pipeline Offers Disease Modifying Potential
3.7.9 Other Mechanisms of Action: Market Projections, 2016-2026
4. Leading Companies in the PD Drug Market, 2016
4.1 PD: Novartis sales of Stalevo/Comtan
4.1.1 Market Forecast for Comtan/Stalevo, 2016-2026
4.2 Teva’s Azilect: Past, Present and Future
4.2.1 Market Forecast for Azilect, 2015-2026
4.3 UCB’s Leading Neupro Patch Drug
4.3.1 Market Forecast for Neupro, 2016-2026
4.4 Other Market Players
5. The Leading National Markets, 2016-2026
5.1 Regional Breakdown of the World PD Drug Market, 2016
5.2 The World PD Drug Market: Regional Forecasts to 2026
5.3 The PD Drug Market in the US: The Largest Single National Market
5.3.1 Market Projections for the US, 2015-2026
5.4 The PD Drug Market in the Five Leading European National Markets (EU5), 2016-2026
5.4.1 Market Projections for the EU5, 2016-2026
5.4.2 EU5 Breakdown by Country, 2016
5.4.3 Market Projection for EU5 Countries, Regional Breakdown
5.4.4 Germany: The Largest EU5 Market
5.4.5 France: Strong Healthcare System – What’s Possible There?
5.4.6 UK’s Spending Restrictions Affect the PD Drugs Market
5.4.7 Spain – What Effects Will Austerity Have on PD Drug Sales?
5.4.8 The PD Drug Market in Italy: Rising and Ageing Population
5.5 Japan has the Highest Proportion of Over-65s in the World
5.5.1 Predictions for Japanese PD Drug Market, 2016-2026
5.6 PD Drug Market in Emerging Countries: Brazil, Russia, India and China (BRIC)
5.6.1 Breakdown of BRIC Revenues by Country, 2016
5.6.2 Market Projections for BRIC Nations’ PD Drug Sales, 2016-2026
5.6.3 Brazil’s Rapid Growth of the Pharma Market – What’s the Future?
5.6.4 Russia’s Healthcare Market Gives Generic Sales Opportunities
5.6.5 India: Generic Manufacturers Seek to Dominate the PD Market
5.6.6 China’s Ageing Population Stimulates Sales of PD-Treating Medicines
6. Research and Development for Treating Parkinson’s Disease
6.1 New Mechanisms of Action in the Late-Stage R&D Pipeline
6.2 Growing Potential of Marketed Products: Phase IV Studies
6.3 Phase III Clinical Products Promising Potential in the PD market
6.3.1 IPX203 (Impax Laboratories): The New Generation of Levodopa
6.3.2 Newron’s Safinamide Expected Launch in 2020
6.3.3 Pimavanserin: A First-in-Class Treatment for Parkinson's Disease Psychosis
6.3.4 Istradefylline: A Promising A(2a) Receptor Antagonist
6.3.5 Termination of Preladenant, APromising A(2a) Receptor Antagonist
6.3.6 Levodopa/Carbidopa Intestinal Gel (LCIG)
6.3.7 Can Opicapone Compete with Existing COMT Inhibitors
6.3.8 Pitolisant: Addressing an Unmet Need
6.3.9 Northera: Oral Precursor of Norepinephrine
6.3.10 Targin by Mundipharm
6.3.11 Nurelinfor Levodopa-Induced Dyskinesia
6.3.12 SYN-115/120: Superior to Istradefylline?
6.4 Phase II PD Pipeline: Overview
6.4.1 Glutamatergic Drugs: Main Target for Pipeline Candidates
6.4.2 Fipamezole: Another Promising A(2a) Receptor Antagonist
6.4.3 CVT-301: A Novel Intrapulmonary Approach
6.4.4 DM-1992: Can Compete with Levodopa Reformulations?
6.4.5 The Accordion Pill Carbidopa/Levodopa by Intec Pharma
6.4.6 Orient Addresses Sialorrhoea
6.4.7 NH004: Formulated with a Muco-Adhesive Property
6.4.8 VR040: A Reformulation of Apomorphine
6.4.9 AVP-923: A Novel Approach for LID-PD
6.4.10 PD Giant Orion, Develop a New Levodopa Drug, ODM-101
6.4.11 News for NeuroDerm’s Reformulations
6.5 Phase I and Pre-clinical PD Pipeline: Overview
6.5.1 Vernalis’ A(2a) Receptor Antagonist Drug in Phase Ib/IIa
6.5.2 Sanofi Collaborates with The Michael J. Fox Foundation
6.5.3 UCL Show Exenatide Potential in Parkinson’s
6.5.4 Titan Pharmaceuticals Develop a Novel Platform
6.6 Neuroprotective Drugs Offer Hope
6.6.1 Phytopharm and Cogane Development
6.6.2 The Potential of Dietary Supplements
6.6.3 GCase Enzymes: Amicus and Biogen Strike A Deal for Parkinson’s
6.6.4 Research Finds Ursodeoxycholic Acid (UDCA) A Potential Cure for Parkinson’s
6.6.5 PD Biomarkers: Potential for Revolutionising Diagnosis and Treatment
6.6.6 Antibody Targeting: The Coming of Age
6.7 Gene Therapy: Promising Research and Technology
6.7.1 ProSavin: Leading Gene Therapy Product
6.7.2 CERE-120 Promises Repair of Damaged Dopaminergic Neurons
6.7.3 AAV-hAADC-2: Another Gene Therapy Contender
6.8 Parthenogenesis (International Stem Cell Corporation): A Promising Outlook for PD Technology
7. Qualitative Analysis of the PD Drug Market, 2016
7.1 SWOT Analysis of the PD Market
7.1.1 Strengths and Weaknesses in the PD Drug Industry in 2016
7.1.2 Opportunities and Threats There from 2016 Onwards
7.2 STEP Analysis of the PD Market
7.2.1 Social Implication of Living with PD
7.2.2 Technological Developments on the Horizon
7.2.3 Economic Pressures: Healthcare Budgeting
7.2.4 Political Issues: Patent Challenges, Data Exclusivity and Regulatory Pathways
8. Research Interviews
8.1 Interview with Dr. Russell Kern (Executive VP, Chief Scientific Officer): International Stem Cell Corporation, California, US
8.1.1 The Overall PD Market
8.1.2 Current Understanding of Stem Cell Therapy
8.1.3 ISCO’s Novel PD Programme
8.1.4 The Potential of Immune-Matching
8.1.5 The Controversy Surrounding Stem Cell Research
8.1.6 The Potential for Parthenogenesis in PD and Other Applications
8.2 Professor Jian Feng PhD, Department of Physiology and Biophysics, University at Buffalo, the State University of New York
8.2.1 A possible Cure
8.2.2 Future Potential: Research
9. Conclusions from the Research and Analysis
9.1 The World PD Market: Predictions to 2026
9.2 Which Therapeutic Class will Dominate the Market in 2026?
9.3 Disease Modification: The Ultimate Goal
9.4 The Future of the Industry and Market for Parkinson’s Medicines
Some Associated Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
List of Tables
Table 1.1 Parkinson’s disease Market: Revenue Forecasts by Sector ($bn), Annual Growth (%) and CAGR, 2016-2026
Table 1.2 Currency Exchange Rates, 2016
Table 2.1 Overview of the Therapeutic Drug Classes for PD, 2015
Table 3.1 World Parkinson’s Disease Drug Market, Revenue ($m), AGR (%), CAGR (%), 2015-2020
Table 3.2 World Parkinson’s Disease Drug Market, Revenue ($m), AGR (%), CAGR (%),
2021-2026
Table 3.3 PD Market Segmentation, Revenues ($m), Market Shares (%), 2016
Table 3.6 Formulations of Levodopa Therapy, 2016
Table 3.7 Dopaminergic Agents Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 3.8 Dopaminergic Agents Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 3.9 Overview of Therapeutic Drug Classes in PD Therapy, 2016
Table 3.10 Dopamine Receptor Agonists Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 3.11 Dopamine Receptor Agonists Segment Forecast, Revenues ($m), AGR (%),
CAGR (%), Market Share (%), 2021-2026
Table 3.12 COMT Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 3.13 COMT Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 3.14 MAO Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR(%), Market Share (%), 2015-2020
Table 3.15 MAO Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR(%), Market Share (%), 2021-2026
Table 3.16 Other Mechanisms of Action Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 3.17 Other Mechanisms of Action Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 4.1 Comtan/Stalevo Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2020
Table 4.2 Comtan/Stalevo Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
Table 4.3 Teva’s Azilect Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2020
Table 4.3.1 Teva’s Azilect Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
Table 4.4 Lundbeck’s Azliect Forecast: Revenues ($m), AGR (%), CAGR (%),
2015-2020
Table 4.4.1 Lundbeck’s Azliect Forecast: Revenues ($m), AGR (%), CAGR (%),
2021-2026
Table 4.5 UCB’s Neupro Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2020
Table 4.5.1 UCB’s Neupro Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
Table 5.2 PD Market Breakdown by Region, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.3 PD Market Breakdown by Region, Revenues ($m), AGR (%), CAGR (%),
Market Share (%), 2021-2026
Table 5.4 US PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.5 US PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.6 EU5 PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.7 EU5 PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.8 EU5 Regional Breakdown by Country, Revenues ($m), Market Share (%), 2016
Table 5.9 EU5 Regional Breakdown by Country, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.10 EU5 Regional Breakdown by Country, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.11 German PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.12 German PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.13 French PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.14 French PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.15 UK PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.16 UK PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.17 Spanish PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.18 Spanish PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.19 Italian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.20 Italian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.21 Japanese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.22 Japanese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.23 BRIC PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.24 BRIC PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.25 BRIC Regional Breakdown by Country, Revenues ($m),BRIC Market Shares (%), 2016
Table 5.26 BRIC PD Drug Market Breakdown by Country, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.27 BRIC PD Drug Market Breakdown Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.28 Brazilian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.29 Brazilian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.30 Russian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.31 Russian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.32 Indian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.33 Indian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.34 Chinese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.35 Chinese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.1 Late-Stage PD Pipeline, 2016
Table 6.2 Reformulations of Levodopa and Other Dopaminergic Agents in Development, 2013
Table 6.3 Phase II PD Pipeline, 2016
Table 6.4 Glutamatergic PD Pipeline, 2016
Table 6.5 Early-Stage Developments for PD, 2013
Table 6.6 Selected Gene Therapies in the PD Pipeline, 2015
Table 7.2 Parkinson’s Disease Drug Market: Opportunities and Threats, 2016-2026
Table 7.3 PD Drug Market: STEP Analysis, 2016
List of Figures
Figure 1.1 Global Parkinson’s disease Market Segmentation Overview, 2015
Figure 3.2 PD Market Segmentation ($m), Market Shares (%), 2016
Figure 3.3 PD Drug Market Breakdown by Segment, Revenues ($m), 2015-2026
Figure 3.4 PD Drug Market, Drivers and Restraints, 2015-2026
Figure 3.5 Dopaminergic Agents Segment Forecast, Revenues ($m), 2015-2026
Figure 3.6 Dopaminergic Agents Market: Drivers and Restraints, 2016-2026
Figure 3.7 Dopaminergic Receptor Agonists Segment Forecast, Revenues ($m), 2015-2026
Figure 3.8 Dopamine Receptor Agonists Market, Drivers and Restraints, 2015-2026
Figure 3.9 COMT Inhibitors Segment Forecast, Revenues ($m), 2015-2026
Figure 3.10 COMT Inhibitors Market, Drivers and Restraints, 2015-2026
Figure 3.11 MAO Inhibitors Segment Forecast, Revenues ($m), 2015-2026
Figure 3.12 MAO Inhibitors Market, Drivers and Restraints, 2016-2026
Figure 3.13 Other Mechanisms of Action Segment Forecast, Revenues ($m), 2015-2026
Figure 3.14 Other Mechanisms of Action, Market Drivers and Restraints, 2015-2026
Figure 4.1 Revenues ($m) of Parkinson’s Drugs by Leading Company, 2013-2015
Figure 4.2 Orion’s Comtan/Stalevo Drug Revenues ($m) Forecast, 2014-2026
Figure 4.3 Teva’s Azilect Drug Revenues Forecast, 2014-2026
Figure 4.3.1 Lundbeck’s Azilect Drug Revenues Forecast, 2014-2026
Figure 5.1 PD Market Breakdown by Region, Market Shares (%), 2016
Figure 5.2 PD Drug Market Breakdown by Region, Revenues ($m), 2013-2026
Figure 5.3 US Over-65 Population as Percentage of Overall Population, 2015-2026
Figure 5.4 US PD Drug Market, Revenue Forecast ($m), 2015-2026
Figure 5.5 EU5 PD Drug Market, Revenue ($m), 2015-2026
Figure 5.6 EU5 Regional Breakdown by Country, Revenues ($m), Market Share(%), 2016
Figure 5.7EU5 Regional Breakdown by Country, Revenues ($m), 2015-2026
Figure 5.8 Over-65 Population in Germany as Percentage of Overall Population, 2015-2026
Figure 5.9 German PD Drug Market, Revenues ($m), 2015-2026
Figure 5.10 Over-65 Population in France as Percentage of Overall Population, 2015-2026
Figure 5.11 French PD Drug Market, Revenues ($m), 2015-2026
Figure 5.12 Over-65 Population in the UK as a Percentage of Overall Population, 2015-2026
Figure 5.13 UK PD Drug Market, Revenues ($m), 2015-2026
Figure 5.14 Over-65 Population in Spain as Percentage of Overall Population, 2015-2026
Figure 5.15 Spanish PD Drug Market, Revenues ($m), 2015-2026
Figure 5.16 Over-65 Population in Italy as Percentage of Overall Population, 2015-2026
Figure 5.17 Italian PD Drug Market, Revenues ($m), 2015-2026
Figure 5.18: Over-65 Population in Japan as Percentage of Overall Population, 2015-2026
Figure 5.19 Japanese PD Drug Market, Revenues ($m), 2015-2026
Figure 5.20 BRIC PD Drug Market, Revenue ($m), 2015-2026
Figure 5.21 BRIC Regional Breakdown by Country, Revenues ($m), BRIC Market Share (%), 2016
Figure 5.22 BRIC PD Drug Market Breakdown, Revenues ($m), 2015-2026
Figure 5.23 Brazilian PD Drug Market, Revenues ($m), 2015-2026
Figure 5.24 Russian PD Drug Market, Revenues ($m), 2015-2026
Figure 5.25 Indian PD Drug Market, Revenues ($m), 2015-2026
Figure 5.26 Chinese PD Drug Market, Revenues ($m), 2015-2026
Figure 8.1 Parthenogenesis Results in Cells Inheriting a Duplicate Set of HLA genes, which Reduces Immune Rejection
Figure 9.1 PD Drug Market, Overall Revenues ($m), 2015, 2020 and 2026
Figure 9.2 PD Drug Market by Segment, Revenues ($m), 2015, 2020 and 2026
Abbott Laboratories
AbbVie Pharmaceuticals
Acadia Pharmaceuticals
Adamas Pharmaceuticals
Addex Therapeutics
Amgen
Amicus Therapeutics
AmarantusBioSciences
Amylin Pharmaceuticals
Ark Therapeutics
AstraZeneca
Avanir Pharmaceuticals
AxxonisPharma
BIAL - Portela
BiogenIdec
Bioprojet Pharma
Biotie Therapies
Biovail
BoehringerIngelheim
Cardiovascular and Renal Drug Advisory Committee
Ceregene
Chelsea Therapeutics
Civitas Therapeutics
Columbia University
Dainippon Sumitomo Pharma
Depomed
DiaGenic
Domain Therapeutics
Dr. Reddy’sLaboratories
Durin Technologies
Eisai
European Medicines Agency (EMEA/EMA)
Food and Drug Administration (US FDA)
Genzyme
GlaxoSmithKline (GSK)
ImpaxLaboratories
Intec Pharma
International Stem Cell Corporation
Ipsen
JuvantiaPharma
Kyowa Hakko Kirin
Lundbeck
Meiji Seika
Merck & Co.
Merck Serono
Mundipharma Research
Mylan
Napp Pharmaceuticals
National Health Service (NHS, UK)
National Institute for Health and Clinical Excellence (NICE, UK)
National Institute of Neurological Disorders and Stroke (NINDS, US)
National Institutes of Health (NIH, US)
Neuren Pharmaceuticals
Neuroderm
NeuroGeneration
NeuroHealing
Neurologix
Newron Pharmaceuticals
Novartis
NuroPro
Ono Pharmaceuticals
Orient Pharma
Orion
Otsuka Pharmaceuticals
Oxford BioMedica
Parkinson’s UK
Par Pharmaceuticals
Pfizer
Pharmaceutical Research and Manufacturers Association
Phytopharm
Power3 Medical Products
Prothena Corporation
Roche
Roxane Laboratories
Sanofi
Santhera
Schering Plough
Sheffield Institute for Translational Neuroscience
SK Biosciences
Skye Pharma
Sun Pharmaceuticals
Technion-Israel Institute of Technology
Teva Pharmaceutical Industries
The Michael J. Fox Foundation
The Parkinson Study Group
Titan Pharmaceuticals
UCB
uniQure
University at Buffalo, the State University of New York
University College London (UCL)
Valeant
Varinel
Vectura Group
Vernalis
Watson Pharmaceuticals
Wockhardt
XenoPort
Zambon Group
Download sample pages
Complete the form below to download your free sample pages for Parkinson’s Diseases: World Drug Industry and Market 2016-2026Download sample pages
Complete the form below to download your free sample pages for Parkinson’s Diseases: World Drug Industry and Market 2016-2026If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
What are the dynamic growth sectors? where are the regional business opportunities?
Which technologies will prevail and who are the leading companies succeeding in these sectors and why?
If you want definitive answers to business critical questions, discover Visiongain’s full range of business intelligence reports.
If so, please email Sara Peerun on sara.peerun@visiongain.com or call her today on +44 (0) 20 7549 9987
- Pharma Wholesale and Distribution Market 2018-2028
- Genomics Market Report 2018-2028
- Top 20 Asthma & COPD Companies 2019
- Human Microbiome Therapeutics Market 2019-2029
- Top 20 Urology Companies 2019
- Global Antidepressant and Anti-Anxiety Drugs Market Forecasts 2019-2029
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Kuwait Pharmaceutical Association
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Generic Medicines Association
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
“Global Acute Myeloid Leukaemia market set to grow to $2.8bn by 2022” says new Visiongain report
Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults and among the most lethal. In the United States, the annual incidence of AML is 19 000 new cases, and the incidence of AML-associated deaths is 10 000.
21 September 2018
“Cell-Based Assay market set to grow to $22bn by 2022” says new Visiongain report
Cell-based assays hold a number of advantages over traditional biochemical assays and animal models, and these advantages have driven the increased demand for these assays in recent years.
18 September 2018
Non-Small Cell Lung Cancer (NSCLC) Drugs Market To Be Worth $8.8bn In 2019, A New Visiongain Analysis Predicts
That investigation gives revenue predictions to 2025 at overall world market, submarket, product and national level.
14 September 2018
The Cholesterol-Lowering Drugs Market Will Reach $24.63bn In 2019 Predicts New Visiongain Report
Recent financial performance is analysed, along with a breakdown of each company’s leading products and an analysis of news that may influence the course of the company.
14 September 2018
